Rimegepant
Rimegepant 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Acute Treatment of Migraine、Migraine。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
17 项
全球在招研究
10 项
已进入 III/IV 期
23 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Pfizer
- IRCCS San Raffaele Roma
- Hospital Universitari Vall d'Hebron Research Institute
- University of Florence
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Medstar Health Research Institute
- Antonios Likourezos
- University of South Florida
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
意大利、美国、Argentina、Chile、Colombia、Croatia、德国、Malaysia、挪威、Poland、Portugal、西班牙
正在招募患者的 Rimegepant 研究
i-NEED: NEw migrainE Drugs Database
不适用招募中意大利NCT07103694Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
不适用招募中美国ArgentinaChileColombiaNCT07159750Gepant treAtments: EffectIveNess and tolERability (GAINER)
不适用招募中意大利NCT05903027Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
III 期招募中美国Poland西班牙NCT04743141Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy
I 期招募中中国NCT07835035Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US
IV 期招募中美国NCT07301008A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
III 期招募中美国Argentina加拿大中国NCT06641466Randomized Study in Children and Adolescents With Migraine: Acute Treatment
III 期招募中美国加拿大中国日本NCT04649242A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India
IV 期招募中IndiaNCT07685769Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
III 期招募中美国加拿大法国意大利NCT05156398A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
IV 期招募中美国NCT06473597A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
I 期招募中美国NCT07667621RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
不适用招募中意大利NCT06409832Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
不适用招募中美国NCT05046613A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
III 期招募中美国IsraelNCT07729462Acute Treatment of Vestibular Migraine by Rimegepant
IV 期招募中中国NCT07871097A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
IV 期招募中美国IsraelNCT07609914
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。